Stem definition | Drug id | CAS RN |
---|---|---|
analogues of penicillanic acid antibiotics modified in the five-membered ring | 1046 | 153832-46-3 |
Dose | Unit | Route |
---|---|---|
1 | g | P |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 38 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 28.72 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
Vd (Volume of distribution) | 0.12 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 0.45 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.10 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 3.80 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
April 18, 2002 | EMA | Merck Sharp & Dohme Ltd | |
Nov. 21, 2001 | FDA | MERCK SHARP DOHME |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Seizure | 145.99 | 22.19 | 100 | 3506 | 122954 | 46559502 |
Confusional state | 112.13 | 22.19 | 95 | 3511 | 159797 | 46522659 |
Hallucination | 108.95 | 22.19 | 60 | 3546 | 49891 | 46632565 |
Mental status changes | 57.26 | 22.19 | 36 | 3570 | 38052 | 46644404 |
Macular degeneration | 55.86 | 22.19 | 21 | 3585 | 7184 | 46675272 |
Clostridium difficile infection | 54.22 | 22.19 | 30 | 3576 | 25073 | 46657383 |
Mitochondrial toxicity | 49.26 | 22.19 | 10 | 3596 | 337 | 46682119 |
Encephalopathy | 46.13 | 22.19 | 30 | 3576 | 33559 | 46648897 |
Avian influenza | 44.49 | 22.19 | 7 | 3599 | 51 | 46682405 |
Product use in unapproved indication | 44.22 | 22.19 | 44 | 3562 | 90229 | 46592227 |
Skin odour abnormal | 43.67 | 22.19 | 12 | 3594 | 1507 | 46680949 |
Delirium | 43.33 | 22.19 | 30 | 3576 | 37198 | 46645258 |
Generalised tonic-clonic seizure | 41.66 | 22.19 | 26 | 3580 | 27096 | 46655360 |
Hidradenitis | 39.74 | 22.19 | 12 | 3594 | 2103 | 46680353 |
Epilepsy | 39.63 | 22.19 | 24 | 3582 | 23714 | 46658742 |
Renal graft infection | 39.23 | 22.19 | 7 | 3599 | 116 | 46682340 |
Status epilepticus | 36.61 | 22.19 | 19 | 3587 | 13960 | 46668496 |
Bone marrow eosinophilic leukocyte count increased | 33.74 | 22.19 | 5 | 3601 | 23 | 46682433 |
Klebsiella infection | 32.79 | 22.19 | 14 | 3592 | 6648 | 46675808 |
Allergic hepatitis | 32.76 | 22.19 | 5 | 3601 | 29 | 46682427 |
Wound secretion | 32.60 | 22.19 | 12 | 3594 | 3868 | 46678588 |
Clostridium test positive | 32.36 | 22.19 | 10 | 3596 | 1894 | 46680562 |
Acute generalised exanthematous pustulosis | 31.17 | 22.19 | 15 | 3591 | 9390 | 46673066 |
Tooth discolouration | 30.86 | 22.19 | 8 | 3598 | 804 | 46681652 |
Hallucination, visual | 29.64 | 22.19 | 18 | 3588 | 17855 | 46664601 |
Hypoglycaemia | 29.41 | 22.19 | 28 | 3578 | 54321 | 46628135 |
Drug reaction with eosinophilia and systemic symptoms | 25.74 | 22.19 | 20 | 3586 | 29528 | 46652928 |
Urinary tract infection pseudomonal | 25.73 | 22.19 | 7 | 3599 | 846 | 46681610 |
Scar | 24.94 | 22.19 | 14 | 3592 | 12005 | 46670451 |
Seizure like phenomena | 24.67 | 22.19 | 7 | 3599 | 988 | 46681468 |
Escherichia test positive | 23.85 | 22.19 | 8 | 3598 | 1964 | 46680492 |
Myoclonus | 22.64 | 22.19 | 14 | 3592 | 14338 | 46668118 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Confusional state | 199.57 | 23.46 | 160 | 4142 | 134674 | 29813502 |
Seizure | 194.62 | 23.46 | 139 | 4163 | 98336 | 29849840 |
Hallucination | 112.35 | 23.46 | 76 | 4226 | 48983 | 29899193 |
Myoclonus | 83.71 | 23.46 | 40 | 4262 | 13272 | 29934904 |
Encephalopathy | 83.61 | 23.46 | 54 | 4248 | 32151 | 29916025 |
Delirium | 79.05 | 23.46 | 57 | 4245 | 40574 | 29907602 |
Hallucination, visual | 76.47 | 23.46 | 40 | 4262 | 16073 | 29932103 |
Generalised tonic-clonic seizure | 63.95 | 23.46 | 38 | 4264 | 19513 | 29928663 |
Serotonin syndrome | 53.92 | 23.46 | 33 | 4269 | 17858 | 29930318 |
Status epilepticus | 51.13 | 23.46 | 27 | 4275 | 11045 | 29937131 |
Product use in unapproved indication | 46.45 | 23.46 | 55 | 4247 | 73638 | 29874538 |
Biliary sepsis | 45.99 | 23.46 | 12 | 4290 | 660 | 29947516 |
Drug interaction | 45.61 | 23.46 | 93 | 4209 | 199475 | 29748701 |
Agitation | 41.99 | 23.46 | 45 | 4257 | 54028 | 29894148 |
Pseudomonal sepsis | 38.71 | 23.46 | 15 | 4287 | 2985 | 29945191 |
Neuromyopathy | 37.19 | 23.46 | 11 | 4291 | 961 | 29947215 |
Disorientation | 35.29 | 23.46 | 32 | 4270 | 31386 | 29916790 |
Clostridium difficile colitis | 34.54 | 23.46 | 22 | 4280 | 12746 | 29935430 |
Pathogen resistance | 31.87 | 23.46 | 18 | 4284 | 8392 | 29939784 |
Eosinophilia | 31.85 | 23.46 | 26 | 4276 | 22134 | 29926042 |
Appendicitis perforated | 30.78 | 23.46 | 11 | 4291 | 1747 | 29946429 |
Epilepsy | 29.70 | 23.46 | 24 | 4278 | 20145 | 29928031 |
Drug resistance | 27.63 | 23.46 | 23 | 4279 | 20110 | 29928066 |
Metabolic acidosis | 27.00 | 23.46 | 30 | 4272 | 37431 | 29910745 |
Vitamin B1 deficiency | 25.46 | 23.46 | 6 | 4296 | 216 | 29947960 |
Neurotoxicity | 24.46 | 23.46 | 18 | 4284 | 13164 | 29935012 |
Anticonvulsant drug level decreased | 24.16 | 23.46 | 8 | 4294 | 1011 | 29947165 |
Vitamin A deficiency | 23.76 | 23.46 | 4 | 4298 | 23 | 29948153 |
Source | Code | Description |
---|---|---|
ATC | J01DH03 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS Carbapenems |
FDA CS | M0024174 | Carbapenems |
FDA EPC | N0000175496 | Penem Antibacterial |
MeSH PA | D000900 | Anti-Bacterial Agents |
MeSH PA | D000890 | Anti-Infective Agents |
CHEBI has role | CHEBI:36047 | antibacterial drugs |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Acute bacterial peritonitis | indication | 31860008 | |
Bacterial pneumonia | indication | 53084003 | DOID:874 |
Miscarriage with sepsis | indication | 67465009 | |
Haemophilus influenzae pneumonia | indication | 70036007 | |
Abdominal abscess | indication | 75100008 | |
Female genital tract infection | indication | 125585007 | |
Infectious disease of abdomen | indication | 128070006 | |
Pneumococcal pneumonia | indication | 233607000 | |
Escherichia coli urinary tract infection | indication | 301011002 | |
Peptostreptococcus infection | indication | 135341000119101 | |
Urinary tract infection caused by Klebsiella | indication | 369001000119100 | |
Complicated Bacterial Peritonitis | indication | ||
Complicated Skin and Skin Structure Streptococcus Pyogenes Infection | indication | ||
Septic Abortion due to Porphyromonas | indication | ||
Post-Op Gynecologic Infection due to Porphyromonas | indication | ||
Klebsiella Pyelonephritis | indication | ||
Post-Op Gynecological Peptostreptococcus Infection | indication | ||
Complicated E. Coli Peritonitis | indication | ||
Postpartum Endomyometritis due to E. Coli | indication | ||
Postpartum Endomyometritis due to Streptococcus | indication | ||
Diabetic Foot Infection | indication | ||
Streptococcal Septic Abortion | indication | ||
Postpartum Endomyometritis due to Peptostreptococcus | indication | ||
Post-Op Gynecologic Infection due to Bacteroides | indication | ||
Postpartum Endomyometritis due to Bacteroides | indication | ||
E. Coli Septic Abortion | indication | ||
E. Coli Pyelonephritis | indication | ||
Complicated Skin and Skin Structure Staphylococcus Aureus Infection | indication | ||
Complicated Skin and Skin Structure E. Coli Infection | indication | ||
Peptostreptococcus Septic Abortion | indication | ||
Complicated Bacteroides Peritonitis | indication | ||
Moraxella Catarrhalis Pneumonia | indication | ||
Post-Op Gynecologic Infection due to Prevotella | indication | ||
Bacteroides Septic Abortion | indication | ||
Colorectal Surgery Infection Prevention | indication | ||
Postpartum Endomyometritis due to Porphyromonas | indication | ||
Post-Op Gynecological Infection due to E. Coli | indication | ||
Postpartum Endomyometritis due to Prevotella | indication | ||
Post-Op Gynecologic Infection, due to Streptococcus | indication | ||
Prevotella Septic Abortion | indication | ||
Complicated Skin and Skin Structure Infection | indication | ||
Gas gangrene caused by clostridium perfringens | off-label use | 266093005 | |
Clostridium Perfringens Empyema | off-label use | ||
Acute nephropathy | contraindication | 58574008 | |
Kidney disease | contraindication | 90708001 | DOID:557 |
Seizure disorder | contraindication | 128613002 | |
Lesion of brain | contraindication | 301766008 | |
Pseudomembranous enterocolitis | contraindication | 397683000 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 2.79 | acidic |
pKa2 | 4.1 | acidic |
pKa3 | 6.83 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Penicillin-binding protein 1B | Enzyme | INHIBITOR | DRUGBANK | CHEMBL | |||||
Penicillin-binding protein 1A | Enzyme | INHIBITOR | DRUGBANK | CHEMBL | |||||
D-alanyl-D-alanine carboxypeptidase DacB | Enzyme | INHIBITOR | DRUGBANK | CHEMBL | |||||
Penicillin-binding protein 1 | Enzyme | WOMBAT-PK | |||||||
Penicillin-binding protein 2 | Enzyme | WOMBAT-PK | |||||||
D-alanyl-D-alanine carboxypeptidase; D-alanyl-D-alanine carboxypeptidase penicillin-binding protein 6 | Enzyme | WOMBAT-PK | |||||||
Penicillin-binding protein 4 | Enzyme | WOMBAT-PK | |||||||
D-ala-D-ala-carboxypeptidase; D-alanyl-D-alanine carboxypeptidase; D-alanyl-D-alanine carboxypeptidase family protein; Penicillin-binding protein 5 | Enzyme | WOMBAT-PK |
ID | Source |
---|---|
4021283 | VUID |
N0000148720 | NUI |
D04049 | KEGG_DRUG |
153773-82-1 | SECONDARY_CAS_RN |
4021283 | VANDF |
C1120106 | UMLSCUI |
CHEBI:404903 | CHEBI |
1RG | PDB_CHEM_ID |
2RG | PDB_CHEM_ID |
CHEMBL1359 | ChEMBL_ID |
CHEMBL1232 | ChEMBL_ID |
DB00303 | DRUGBANK_ID |
D000077727 | MESH_DESCRIPTOR_UI |
150610 | PUBCHEM_CID |
10906 | IUPHAR_LIGAND_ID |
8049 | INN_ID |
G32F6EID2H | UNII |
325642 | RXNORM |
16218 | MMSL |
173352 | MMSL |
274067 | MMSL |
42474 | MMSL |
d04783 | MMSL |
009554 | NDDF |
009555 | NDDF |
385573008 | SNOMEDCT_US |
385574002 | SNOMEDCT_US |
396346003 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
INVANZ | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0006-3843 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 g | INTRAMUSCULAR | NDA | 28 sections |
INVANZ | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0006-3845 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 g | INTRAVENOUS | NDA | 28 sections |
Ertapenem | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-3510 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 g | INTRAMUSCULAR | ANDA | 28 sections |
ERTAPENEM | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42023-221 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 g | INTRAMUSCULAR | NDA | 29 sections |
ERTAPENEM | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42023-221 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 g | INTRAMUSCULAR | NDA | 29 sections |
ERTAPENEM SODIUM | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43598-901 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 g | INTRAVENOUS | ANDA | 25 sections |
ertapenem | HUMAN PRESCRIPTION DRUG LABEL | 1 | 44567-820 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 g | INTRAMUSCULAR | ANDA | 28 sections |
Ertapenem | HUMAN PRESCRIPTION DRUG LABEL | 1 | 44647-051 | INJECTION | 1 g | INTRAVENOUS | ANDA | 29 sections |
Ertapenem | Human Prescription Drug Label | 1 | 55150-282 | INJECTION | 1 g | INTRAVENOUS | ANDA | 25 sections |
Ertapenem | Human Prescription Drug Label | 1 | 55150-282 | INJECTION | 1 g | INTRAVENOUS | ANDA | 25 sections |
Ertapenem | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60505-6196 | INJECTION | 1 g | INTRAVENOUS | ANDA | 29 sections |
Ertapenem | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-823 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 g | INTRAVENOUS | ANDA | 29 sections |
Ertapenem | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68001-408 | INJECTION | 1 g | INTRAVENOUS | ANDA | 29 sections |
Ertapenam | Human Prescription Drug Label | 1 | 68083-351 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 g | INTRAVENOUS | ANDA | 25 sections |